He describes how Stoke aims to up-regulate healthy genes in cases where diseases are caused by autosomal dominant haploinsufficiencies, like Dravet. He discusses the phase 1/2 data, a phase 3 that is scheduled to read out in 2027, and the regulatory history of the program.

He describes the design of the global pivotal study, which will be initiating soon, why Stoke chose Biogen as a partner, and how today's...

He describes the unique science that Stoke was founded on, how phase 1/2a data in Dravet appears to show they are reversing this genetic...